Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;13(21):e70375.
doi: 10.1002/cam4.70375.

Patient-Initiated Nationwide Survey on Testing for Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer in Japan

Satoshi Ikeda  1 , Kazuo Hasegawa  2   3 , Kenta Kachi  3 , Akihiro Yanagisawa  3 , Sachiko Kawakami  3 , Shinsuke Hamasaki  3 , Sachiko Watanabe  4 , Aki Yoshikawa  4 , Takayuki Takahama  5 , Kazuhiko Nakagawa  5
Affiliations

Patient-Initiated Nationwide Survey on Testing for Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer in Japan

Satoshi Ikeda et al. Cancer Med. 2024 Nov.

Abstract

Background: Previous reports indicated still low implementation rates of multigene testing for advanced non-small cell lung cancer (NSCLC) in Japan.

Methods: This is a retrospective study launched at the initiative of lung cancer patients. Patients with stage IV NSCLC from January 2019 to December 2022 were investigated for testing of 8 actionable oncogenic drivers with targeted therapies available as of 2022.

Results: A total of 15,719 patients were included. Between 2019 and 2022, the percentage of patients who were not tested for any actionable oncogenic drivers remained the same, ranging from 21.5% to 33.1%. However, since late 2021, the percentage of patients tested for five or more actionable oncogenic drivers has increased. Across hospital categories and regions, the number of actionable oncogenic drivers tested was similar.

Conclusions: This patient-initiated national survey in Japan reveals the recent nationwide increase in testing rates for actionable oncogenic drivers in Advanced NSCLC.

Keywords: actionable oncogenic drivers; diagnosis procedure combination; multigene testing; non‐small cell lung cancer; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Satoshi Ikeda received honoraria from AstraZeneca, Bristol Myers Squibb, Ono, Taiho, Chugai, Boehringer Ingelheim, Eli Lilly, Takeda, Pfizer, MSD, Amgen, and Novartis; research funding from AstraZeneca and Chugai; and took on a consulting or advisory roles for AstraZeneca, Chugai and Daiichi Sankyo. Kazuo Hasegawa, Kenta Kachi, Akihiro Yanagisawa, Sachiko Kawakami, Shinsuke Hamasaki, Sachiko Watanabe, and Aki Yoshikawa have no conflicts of interest to declare. Takayuki Takahama received honoraria from AstraZeneca, Chugai, Roche Diagnostics, and MSD; research funding from Takeda and Pfizer. Kazuhiko Nakagawa received honoraria from AstraZeneca, Ono, Chugai, Boehringer Ingelheim, Taiho, Takeda, MSD, Merck, Bayer, Nippon Kayaku, Amgen. Japan Clinical Research Operations, Taiyo Pharma, Eli Lilly, Pfizer, Novartis, Daiichi Sankyo, Bristol Myers Squibb, Janssen, Otsuka, Hisamitsu, CMIC ShiftZero, CMIC Co. Ltd., Incyte biosciences, M3, Inc., Global Health Consulting Japan, YODOSHA, Medical Mobile Communications, Life Technologies and Neo Communication; research funding from AstraZeneca, Chugai, Ono, Daiichi Sankyo, Boehringer Ingelheim, Taiho, IQVIA, EPS Corporation, Bayer, MSD, Otsuka, EPS International, PRA Health Science, Labcorp Development Japan, GlaxoSmithKline, Mochida Pharmaceutical, Japan Clinical Research Operations, Sanofi, Medical Research Support, SYNEOS HEALTH, Nippon Kayaku, Mebix, Janssen, Eli Lilly, Amgen, Novartis, SRL Diagnostics, Takeda, Eisai, Bristol‐Myers Squibb, EP‐CRSU, Pfizer, CMIC, Kobayashi Pharmaceutical, Shionogi, Astellas and Ascent Development Services; and took on a consulting or advisory roles for Eli Lilly and Ono.

Figures

FIGURE 1
FIGURE 1
Annual change of actionable oncogenic drivers tested. Bar chart showing the annual change in the number of actionable oncogenic drivers tested (A) and line chart showing the annual change in testing rates for each oncogenic drivers (B) for patients for whom lung biopsy was performed from January 2019 to December 2022. EGFR, Epidermal Growth Factor Receptor; ALK, Anaplastic lymphoma kinase; ROS1, C‐Ros Oncogene 1; BRAF, B‐Raf Proto Oncogene Serine/Threonine Protein Kinase; MET, MNNG HOS Transforming gene; RET, Rearranged during Transfection; KRAS, V‐Ki‐ras2 Kirsten rat sarcoma viral oncogene homolog; NTRK, Neurotrophic Tropomyosin Receptor Kinase.
FIGURE 2
FIGURE 2
Comparison of the number of actionable oncogenic drivers tested by hospital category and region. Bar charts comparing the number of actionable oncogenic drivers tested by hospital category (A) and by region in Japan (B). Patients who underwent lung biopsy from 2019 to 2021 (left) and those who underwent lung biopsy in 2022 (right) are shown separately. *A “designed cancer care hospital” is a hospital designated by the Ministry of Health, Labour and Welfare of Japan based on the recommendation of prefectural governments to provide high quality cancer treatment.
See this image and copyright information in PMC

References

    1. Sakamoto T., Matsubara T., Takahama T., et al., “Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non‐Small Cell Lung Cancer,” JAMA Network Open 6, no. 12 (2023): e2347700. - PMC - PubMed
    1. Vestergaard L. K., Oliveira D. N. P., Poulsen T. S., Høgdall C. K., and Høgdall E. V., “Oncomine Comprehensive Assay v3 vs. Oncomine Comprehensive Assay Plus,” Cancers 13, no. 20 (2021): 5230. - PMC - PubMed
    1. Murakami S., Yokose T., Nemoto D., et al., “Suitability of Bronchoscopic Biopsy Tissue Samples for Next‐Generation Sequencing,” Diagnostics 11, no. 3 (2021): 391. - PMC - PubMed
    1. Kunimasa K., Matsumoto S., Kawamura T., et al., “Clinical Application of the AMOY 9‐In‐1 Panel to Lung Cancer Patients,” Lung Cancer 179 (2023): 107190. - PubMed
    1. Morikawa K., Kida H., Handa H., et al., “A Prospective Validation Study of Lung Cancer Gene Panel Testing Using Cytological Specimens,” Cancers 14, no. 15 (2022): 3784. - PMC - PubMed